FA
TVTX icon

Forefront Analytics’s Travere Therapeutics TVTX Stock Holding History

Forefront Analytics’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,317
Closed -$109K – 71
2024
Q2 		$109K Buy
13,317
+1,237
+10% +$8.33K 0.05% 63
2024
Q1 		$93.1K Buy
+12,080
New +$102K 0.05% 62

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Forefront Analytics's TVTX Position: Q3 2024 in Review

Forefront Analytics sold out of Travere Therapeutics (TVTX) in Q3 2024, closing a stake of 13,317 shares — an estimated $109K sold.

Forefront Analytics first reported a position in TVTX in Q1 2024 and held it in 2 quarters. The position peaked at $109K in Q2 2024. 178 funds tracked by Wall St. Rank hold TVTX as of Q3 2024.

  • Forefront Analytics reported no remaining Travere Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Forefront Analytics sold 13,317 Travere Therapeutics shares in Q3 2024, an estimated $109K.
  • Forefront Analytics first reported a position in Travere Therapeutics in Q1 2024 and held it in 2 quarters.
  • Forefront Analytics's Travere Therapeutics position peaked at $109K in Q2 2024.
  • 178 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2024.

Based on Forefront Analytics's 13F filing for Q3 2024, filed 14 Nov 2024.